EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity

Nuala Helsby, Katrina Sharples, Yu Jin Kim, David Porter, Kathryn Burns, Soo Hee Jeong, Sarah Benge, Sanjeev Deva, Ben Lawrence, Christopher Jackson, Richard North, R Matthew Strother und 2 weitere

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04804-6 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Nuala Helsby und 13 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. n.helsby@auckland.ac.nz. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Dihydropyrimidine Dehydrogenase Deficiency, Dihydrouracil Dehydrogenase (NADP), Fluorouracil. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Auckland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Inherited dihydropyrimidine dehydrogenase (DPD) deficiency is a risk factor for severe 5-fluorouracil toxicity. We report a phenotyping approach (thymine challenge test) to prospectively determine DPD activity and the association with severe adverse events.

Methods

The primary aim of this prospective study was to determine whether a thymine challenge test could prospectively identify patients at risk of severe toxicity from treatment with 5-fluorouracil/capecitabine in combination chemotherapy schedules or monotherapy. The focus was prediction of those at risk of ≥ grade 3 gastrointestinal toxicity. DPD activity was determined from the thymine/dihydrothymine (THY/DHT) ratio measured in a urine sample after a thymine test dose (250 mg, oral).

Results

Of the 166 patients, 11.7% had severe diarrhoea/mucositis. The THY/DHT ratio was not significantly different in these individuals compared to those with minimal toxicity. However, post hoc analysis found decreased DPD activity in those who had non-gastrointestinal toxicity, most notably grade ≥ 2 Hand-Foot syndrome ( p = 0.001).

Conclusion

The data do not support our primary hypothesis that this phenotyping approach would discriminate those at risk of severe/life-threatening gastrointestinal toxicity. The clinical factors which influence gastrointestinal toxicity, particularly in patients receiving CAPOX require further investigation. Clinical trial registration ACTRN 12,617,001,109,392 registered 28/07/2017.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsDihydropyrimidine Dehydrogenase DeficiencyDihydrouracil Dehydrogenase (NADP)FluorouracilGastrointestinal DiseasesThymineAdultAgedFemaleHumansMaleMiddle AgedAntimetabolites, AntineoplasticCapecitabineDiarrheaProspective Studies

Stichwörter der Autor:innen

5-FU toxicityDPYDDihydropyrimidine dehydrogenase deficiencyThymine

Substanzen

Antimetabolites, AntineoplasticCapecitabineDihydrouracil Dehydrogenase (NADP)FluorouracilThymine

Autor:innen und Institutionen

  • Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. n.helsby@auckland.ac.nz.
  • Cancer Trials New Zealand, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Mathematics and Statistics, University of Otago, Dunedin, New Zealand.
  • Auckland City Hospital, Te Whatu Ora Health New Zealand, Auckland, New Zealand.
  • Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Canopy Cancer Care, 213 Shakespeare Road, Takapuna, Auckland, New Zealand.

Förderung

  • University of Auckland

Zitieren

APA

Helsby, N., Sharples, K., Kim, Y. J., Porter, D., Burns, K., Jeong, S. H., Benge, S., Deva, S., Lawrence, B., Jackson, C., North, R., Strother, R. M., Duley, J., & Findlay, M. (2025). A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04804-6

Vancouver

Helsby N, Sharples K, Kim YJ, Porter D, Burns K, Jeong SH, et al. A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04804-6

BibTeX
@article{Helsby2025,
  author = {Helsby, Nuala and Sharples, Katrina and Kim, Yu Jin and Porter, David and Burns, Kathryn and Jeong, Soo Hee and Benge, Sarah and Deva, Sanjeev and Lawrence, Ben and Jackson, Christopher and North, Richard and Strother, R Matthew and Duley, John and Findlay, Michael},
  title = {A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04804-6}
}
Kostenlos starten →